Merck-Moderna positive Phase 3 melanoma vaccine data lifts IOVA 14% to 52-week high
- Merck & Moderna announced Aug 19 success in late-stage melanoma trial of mRNA vaccine + Keytruda
- Data showed significant improvement in recurrence-free and distant metastasis-free survival
- Sent MRNA shares soaring over 100%; boosted sentiment for melanoma cell therapies like Amtagvi
- IOVA benefits as Amtagvi is approved for advanced melanoma; validates broader immunotherapy space
- Builds on strong Q2 results ($99.3M revenue, $91M Amtagvi US sales, 56% gross margin)
- Mizuho raised PT to $11 from $10 (Outperform) on Aug 18 citing commercial execution
- Anticipation of upward 2026 guidance revision in Q3 added to positive momentum
- Stock closed at $7.99 (+13.66%), new 52-week high amid high volume and retail buzz
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.